BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patie (Información remitida por la empresa firmante) -- The Company will discuss the topline results during its Q4 2022 results presentation on Thursday, February 16, 2023, at 10:00 AM CET - BERGEN, Norway, Feb.
North Holdings 3 Oy supplements the tender offer document relating to the public tender offer for all the shares in Cave
North Holdings 3 Oy supplements the tender offer document relating to the public tender offer for all the shares in Cave
North Holdings 3 Oy supplements the tender offer document relating to the public tender offer for all the shares in Cave
The Nomination Committee's proposal for resolutions at the Annual General Meeting 2023 of Castellum Aktiebolag
Renexxion Ireland Ltd. y Dr. Falk Pharma GmbH anuncian el inicio de un estudio de fase II de naronaprida (2)
Renexxion Ireland Ltd. y Dr. Falk Pharma GmbH anuncian el inicio de un estudio de fase II de naronaprida (1)
